SCHEMBL3487024

SCHEMBL3487024

CNc1nc(Oc2ccc(C)c(F)c2)ccc1N

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 6/20 0.42
PPARG P37231 1/20 0.36
KDM4E B2RXH2 1/20 0.35
POLB P06746 1/20 0.35
KMT2A Q03164 2/20 0.33
MEN1 O00255 1/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
NUDT1 P36639 1/20 0.33
F10 P00742 2/20 0.33
F2 P00734 1/20 0.33
PRSS1 P07477 1/20 0.33
PRSS2 P07478 1/20 0.33
PRSS3 P35030 1/20 0.33
ST14 Q9Y5Y6 1/20 0.33
HAO1 Q9UJM8 1/20 0.32
GCK P35557 2/20 0.32
NR4A1 P22736 1/20 0.32
EGLN1 Q9GZT9 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3487123 0.87 KMT2A (0.44) MAP4K4PPARGKDM4EPOLBKMT2A
SCHEMBL3487078 0.80 MEN1 (0.50) MAP4K4KDM4EPOLBKMT2AMEN1
SCHEMBL3488415 0.79 ALDH1A1 (0.43) MAP4K4KDM4EPOLBKMT2AMEN1
SCHEMBL2944371 0.75 NUDT1 (0.53) MAP4K4KMT2AMEN1MAPTHPGD
SCHEMBL10005545 0.75 KDM4E (0.36) MAP4K4PPARGKDM4EPOLBKMT2A
SCHEMBL10005547 0.72 F10 (0.40) MAP4K4KDM4EPOLBKMT2AMEN1
SCHEMBL29378197 0.69 SIRT2 (0.41) KDM4EPOLBKMT2ASMN1; SMN2
SCHEMBL95212 0.69 SIRT2 (0.41) KDM4EPOLBKMT2ASMN1; SMN2
SCHEMBL23795617 0.69 MAPT (0.42) KDM4EMAPTHPGD
SCHEMBL23952709 0.68 KDM4E (0.46) MAP4K4PPARGKDM4EPOLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2138484-B1 FUSED BICYCLIC HETEROARYL DERIVATIVES DAIICHI SANKYO CO LTD (JP) 2015-08-26 EP disclosed
US-20130035337-A1 FUSED BICYCLIC HETEROARYL DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-02-07 US disclosed
US-20100048564-A1 FUSED BICYCLIC HETEROARYL DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2010-02-25 US disclosed
EP-2138484-A1 FUSED BICYCLIC HETEROARYL DERIVATIVES Daiichi Sankyo Company, Limited (JP) 2009-12-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130035337-A1 FUSED BICYCLIC HETEROARYL DERIVATIVE PPARG, GPR119, PPARA MAP4K4 2382/4885PPARG 1/4885KDM4E 3594/4885
US-20100048564-A1 FUSED BICYCLIC HETEROARYL DERIVATIVE PPARG, GPR119, PPARA MAP4K4 2382/4885PPARG 1/4885KDM4E 3594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.